Экспрессия генов семейства MAGE в культурах клеток 40 увеальной меланомы человека

    1. Zhilnikova MV, Troitskaya OS, Novak DD, Atamanov VV, Koval OA. Uveal melanoma: molecular and genetic mechanisms of development and therapeutic approaches. Mol Biol. 2024;58: 165–77. doi: 10.1134/S0026893324020183

    2. Zhilnikova MV, Atamanov VV, Zvereva SP, Gayner TA, Boyarskikh UA, Stanishevskaya OM, Chernykh DV, Kononova NV, Koval OA. Molecular and genetic analysis of personal cultures of uveal melanoma cells. JOS. 2024;140(2s): 63–71. doi: 10.25276/0235-4160-2024-2S-63-71

    3. Koval O, Zhilnikova M, Balantaeva M, Biryukov M, Atamanov V. Cell death of tumor melanocytes and treatment options. BIOCELL. 2025; 49(3):355-379. doi: 10.32604/biocell.2025.059987

    4. Zhilnikova MV, Novak DD, Troitskaya OS, Nushtaeva AA, Biryukov MM, Zvereva SP, Varlamov ME, Koval VV, Stanishevskaya OM, Chernikh DV, Kononova NV, Atamanov VV, Koval OA. A new human uveal melanoma cell line: melanin production and molecular markers for targeted therapy. Biochem Moscow Suppl Ser B. 2023;17: 165–171. doi: 10.1134/S1990750823600607

    5. Poojary M, Jishnu PV, Kabekkodu SP. Prognostic value of melanoma-associated antigen-A (MAGE-A) gene expression in various human cancers: A systematic review and meta-analysis of 7428 patients and 44 studies. Mol Diagn Ther. 2020;24: 537–555. doi: 10.1007/s40291-020-00476-5

    6. Lee AK, Potts PR. A comprehensive guide to the MAGE family of ubiquitin ligases. J Mol Biol. 2017;429: 1114–1142. doi: 10.1016/j.jmb.2017.03.005

    7. Li S, Shi X, Li J, Zhou X. Pathogenicity of the MAGE family (Review). Oncol Lett. 2021;22: 844. doi: 10.3892/ol.2021.13105

    8. De Plaen E, Traversari C, Gaforio JJ, Szikora J-P, De Smet C, Brasseur F, Van Der Bruggen P, Lethé B, Lurquin C, Chomez P, De Backer O, Boon T, Arden K, Cavenee W, Brasseur R. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 1994;40: 360–369. doi: 10.1007/BF01246677

    9. Doyle JM, Gao J, Wang J, Yang M, Potts PR. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Molecular Cell. 2010;39: 963–74. doi: 10.1016/j.molcel.2010.08.029

    10. Ravichandran R, Kodali K, Peng J, Potts PR. Regulation of MAGE ‐A3/6 by the CRL 4‐DCAF 12 ubiquitin ligase and nutrient availability. EMBO Reports. 2019;20: e47352. doi: 10.15252/embr.201847352

    11. Pineda CT, Ramanathan S, Fon Tacer K, Weon JL, Potts MB, Ou Y-H, White MA, Potts PR. Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell. 2015;160: 715–728. doi: 10.1016/j.cell.2015.01.034

    12. Jin X, Pan Y, Wang L, Zhang L, Ravichandran R, Potts PR, Jiang J, Wu H, Huang H. MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation. Oncogenesis. 2017;6: e312–e312. doi: 10.1038/oncsis.2017.21

    13. Zamunér FT, Karia BTR, De Oliveira CZ, Santos CRD, Carvalho AL, Vettore AL. A comprehensive expression analysis of cancer testis antigens in head and neck squamous cell carcinoma revels MAGEA3/6 as a marker for recurrence. Molecular Cancer Therapeutics. 2015;14: 828–834. doi: 10.1158/1535-7163.MCT-14-0796

    14. Bertrand M, Huijbers I, Chomez P, De Backer O. Comparative expression analysis of the MAGED genes during embryogenesis and brain development. Dev Dyn. 2004;230: 325–334. doi: 10.1002/dvdy.20026

    15. Radi A, Nasrah S, Auer M, Renigunta A, Weber S, Seaayfan E, Kömhoff M. MAGED2 enhances expression and function of NCC at the cell surface via cAMP signaling under hypoxia. Cells. 2025;14: 175. doi: 10.3390/cells14030175

    16. Yan J, Li S, Lenahan C, Chen H, Wen J, Huang Q, Jiang Q, Guo F, Deng T, Mo L. Expression and prognostic value of melanoma-associated antigen D2 in gliomas. Brain Sci. 2022;12: 986. doi: 10.3390/brainsci12080986

    17. The Cancer genome atlas program. The Website of the National Cancer Institute. Available from: https://portal.gdc.cancer.gov/ [Accessed 18th June 2025]

    18. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA. 1996;93: 7149–7153. doi: 10.1073/pnas.93.14.7149

    19. Gelmi MC, Gezgin G, Van Der Velden PA, Luyten GPM, Luk SJ, Heemskerk MHM, Jager MJ. PRAME expression: A target for cancer immunotherapy and a prognostic factor in uveal melanoma. Invest Ophthalmol Vis Sci. 2023;64: 36. doi: 10.1167/iovs.64.15.36

    20. Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis. 1997;15: 509–518. doi: 10.1023/A:1018479011340

    21. Errington JA, Conway RM, Walsh-Conway N, Browning J, Freyer C, Cebon J, Madigan MC. Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma. Br J Ophthalmol. 2012;96: 451–458. doi: 10.1136/bjophthalmol-2011-300432

    22. Tseng H-Y, Chen LH, Ye Y, Tay KH, Jiang CC, Guo ST, Jin L, Hersey P, Zhang XD. The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells. Carcinogenesis. 2012;33: 1871–1881. doi: 10.1093/carcin/bgs236